| Axon ID |
Name |
Description |
From price |
|
1394
|
Imatinib mesylate
|
Bcr-Abl, c-KIT and PDGFR kinase inhibitor |
€60.00 |
|
1398
|
Sunitinib malate
|
Multi-targeted receptor tyrosine kinase inhibitor |
€80.00 |
|
1414
|
AG 013736
|
PDGFR,c-KIT and VEGFR tyrosine kinase inhibitor |
€50.00 |
|
1415
|
CT 53518
|
PDGFR, c-KIT and FLT3 tyrosine kinase inhibitor |
€70.00 |
|
1416
|
NVP-TAE684
|
NPM-ALK inhibitor |
€50.00 |
|
1419
|
AB 1010
|
PDGFR, c-KIT and FGFR3 tyrosine kinase inhibitor |
€70.00 |
|
1420
|
Pazopanib hydrochloride
|
PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor |
€60.00 |
|
1547
|
OSI 930
|
c-Kit and VEGFR2 tyrosine kinase inhibitor |
€90.00 |
|
1581
|
SU 11274
|
ATP-competitive inhibitor of c-MET |
€90.00 |
|
1582
|
Foretinib
|
c-MET and VEGFR2 tyrosine kinase inhibitor |
€90.00 |
|
1583
|
PF 04217903 mesylate
|
c-MET tyrosine kinase Inhibitor |
€80.00 |
|
1638
|
ABT 869
|
PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor |
€85.00 |
|
1678
|
Regorafenib
|
Multi-kinase RTK inhibitor |
€70.00 |
|
1696
|
Quizartinib dihydrochloride
|
FLT3 inhibitor |
€90.00 |
|
1768
|
AMG 706
|
Multiple receptor tyrosine kinase inhibitor |
€105.00 |
|
1819
|
Cabozantinib S-malate
|
Inhibitor of multiple receptor tyrosine kinases, specifically MET and VEGFR2 |
€60.00 |
|
1838
|
ARQ 197
|
c-MET tyrosine kinase Inhibitor |
€90.00 |
|
1884
|
Alectinib
|
Orally available and selective ALK inhibitor |
€70.00 |
|
1891
|
SU 6668
|
Inhibitor of RTK targeting PDGFR, VEGF and FGFR |
€100.00 |
|
1914
|
SGX 523
|
ATP-competitive inhibitor of c-MET |
€120.00 |
|
1916
|
AMG 208
|
Inhibitor of c-MET receptor tyrosine kinase (RTK) |
€95.00 |
|
1959
|
Golvatinib
|
Potent and orally available inhibitor of c-MET (HGFR) and VEGFR2 |
€90.00 |
|
2005
|
ASP 3026
|
Inhibitor of the oncogenic fusion kinase EML4-ALK |
€80.00 |
|
2153
|
AZD3463
|
Potent inhibitor of ALK and IGF1R |
€105.00 |
|
2224
|
LDK 378
|
Potent, bioavailable, and selective anaplastic lymphoma kinase (ALK) inhibitor |
€95.00 |
|
2267
|
GSK 1838705A
|
Potent IGF-IR and insulin receptor (IR) kinase inhibitor with additional affinity for ALK |
€110.00 |
|
2296
|
(S)-Crizotinib
|
MTH1 inhibitor |
€85.00 |
|
2368
|
Amuvatinib
|
RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met |
€105.00 |
|
2294
|
KRCA 0008
|
Potent and selective dual ALK/ACK1 inhibitor with good drug-like properties |
€95.00 |
|
2501
|
Pexidartinib
|
Mutil-targeted RTK inhibitor of CSF1R, c-Kit, and FLT3 |
€60.00 |
|
2553
|
LY 2801653
|
Orally bioavailable multi-kinase inhibitor with potent activity against c-MET |
€120.00 |
|
2600
|
PF 06463922
|
Potent, orally available and brain-penetrant ALK/ROS1 selective inhibitor |
€105.00 |
|
2767
|
SU11652
|
Multi-targeted receptor tyrosine kinase inhibitor |
€140.00 |
|
2978
|
Brigatinib
|
Potent, selective, and orally active anaplastic lymphoma kinase (ALK) inhibitor |
€80.00 |
|
3423
|
Capmatinib
|
Highly potent, selective, ATP competitive and orally bioavailable c-MET inhibitor |
€80.00 |
|
3864
|
Volitinib dihydrochloride
|
ATP-competitive small molecule c-Met kinase inhibitor |
Inquire |
|
3931
|
CEP-28122
|
Highly potent, selective and orally active ALK inhibitor |
Inquire |
|
3945
|
AMG-337
|
Potent and exquisitely selective inhibitor of wild-type and some mutant forms of c-Met |
Inquire |
|
3946
|
Altiratinib
|
Balanced inhibitor for MET, TIE2 (TEK), and VEGFR2 (KDR) kinases |
Inquire |
|
3973
|
XL-228
|
Multitargeted protein kinase inhibitor (IGF1R, Aurora,FGFR, ABL,ALK and SRC) |
Inquire |
|
3975
|
MGCD265 dihydrochloride
|
Orally active, potent MET/SMO dual inhibitor |
€130.00 |
|
4038
|
CEP-37440 hydrochloride
|
Potent, selective and orally active inhibitor of ALK anf FAK |
Inquire |
|
4040
|
BMS-777607
|
potent, selective and orally bioavailable c-Met inhibitor |
Inquire |